WithdrawnPhase 2

Study of FTY720 in Patients With Uveitis

0Started 2013-11

Plain-language summary

This study will assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Acute noninfectious posterior, intermediate, or pan uveitis * Vitreous haze score of 1+ or more in the study eye at screening and baseline visits Exclusion Criteria: * Vaso-occlusive vasculitis involving the retinal macula * Behçet's uveitis * Patients requiring corticosteroid or another systemic immunosuppressive medication for any other disease (e.g., asthma or some other autoimmune disease) that would contraindicate tapering (topical steroids permitted) * Other protocol defined inclusions and/or exclusions may apply.

What they're measuring

Change in Vitreous Haze Score in the Study Eye at Day 8

Timeframe: Day 8

Trial details

NCT IDNCT01791192

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2014-10

View on ClinicalTrials.gov More Acute Noninfectious Posterior, Intermediate, or Pan Uveitis trials